Jump to content
RemedySpot.com

Supreme Court

Rate this topic


Recommended Posts

Posted

Might the following have an impact on the Supplement Industry?

Can the Supplement Industry rally together for certain court-approved

protections?

Supremes leaning toward pre-emption?

<http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,g384,dj45,65c6,97w5

>

Comment

<http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,3lk0,lt86,65c6,97w5

#comment> | Forward to a friend

<http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,6l7a,ienb,65c6,97w5

>

Yesterday court-watchers got another sneak peek at which way the Supreme

Court might lean when they hear the big drug liability case next term.

In hearing arguments over Michigan's law that shields pharma from

liability suits unless they commit fraud to get their drug approved,

Justices Breyer and Kennedy " expressed broad skepticism "

about liability suits against drug makers, Forbes reports. Breyer

said--and this is key--that the suits second-guess the FDA's decision to

approve the drug. An expert agency is better qualified to make decisions

about a drug's safety than is a jury of 12 randomly selected citizens,

Breyer said.

Of course, that sentiment is just what drugmakers would like to see

borne out when the Court takes on the case of Wyeth v. Levine in

October. In that case, the court is being asked to determine whether FDA

approval pre-empts personal injury lawsuits. Last week, the Supremes

decided that for medical devices, a specific type of rigorous FDA

approval does shield manufacturers from liability suits

<http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,6f68,hite,65c6,97w5

> .

If the wind were ever blowing in drugmakers' favor on this issue, it's

now. Before the Bush administration, the FDA argued that lawsuits gave

patients additional protection, the New York Times notes. Now, the

administration says

<http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,els8,4gwj,65c6,97w5

> lawsuits conflict with the agency's ability to do its job. So,

apparently, believes Justice Alito, who asked yesterday whether a

state lawsuit should be allowed to proceed even though it might " very

seriously interfere with what the FDA is doing. "

Ironically, part of the government's argument in this case is that the

FDA competently oversees the drug and device markets. An assessment

that, after recent expert critique and importation snafus, is certainly

open to question

<http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,8y8r,egys,65c6,97w5

> .

- read the Forbes article

<http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,lijd,bqvy,65c6,97w5

>

- check out the NYT article

<http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,20x1,e7bw,65c6,97w5

>

Court Struggles With Pharma Suits

By CHRISTOPHER S. RUGABER 02.25.08, 4:44 PM ET

WASHINGTON -

The Supreme Court on Monday wrestled with a Michigan law that shields

pharmaceutical companies from product liability lawsuits, unless they

committed fraud to get their drug approved.

At issue is whether that fraud exception, which allows lawsuits to

proceed, is preempted by federal regulation of pharmaceuticals.

, a lawyer for Pfizer Inc. (nyse: PFE

<http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp?

tkr=PFE> - news

<http://www.forbes.com/markets/company_news.jhtml?ticker=PFE> - people

<http://www.forbes.com/peopletracker/results.jhtml?startRow=0 & name= & tick

er=PFE> ), told the justices that it should be.

" There is a very unique federal interest " in the Food and Drug

Administration's regulation of pharmaceuticals, he said. " There is no

legitimate state interest here. "

The dispute stems from several suits against Warner-Lambert over its

diabetes drug Rezulin. Warner-Lambert is now owned by Pfizer.

Justices Breyer and Kennedy appeared to side with

Pfizer, expressing broad skepticism about product liability suits

against pharmaceutical companies. Breyer said they essentially

second-guess the FDA's decision to approve the drug.

Breyer's remarks are significant because the court has already accepted

a case for its next term, which begins in October, that takes on the

broader issue of when drug companies can be held liable for products

that have been approved by the FDA. That case is Wyeth v. Levine,

06-1249.

Other justices, however, were more sympathetic to allowing the suits to

proceed. Justice s dismissed concerns raised by the Bush

administration that they would prove burdensome to the FDA as

" theoretical. "

Monday's case is one of several before the court that tests the limits

of federal preemption of state regulations in areas such as drugs,

medical devices and online tobacco sales.

The justices ruled last Wednesday in a case involving Medtronic Inc.

(nyse: MDT

<http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp?

tkr=MDT> - news

<http://www.forbes.com/markets/company_news.jhtml?ticker=MDT> - people

<http://www.forbes.com/peopletracker/results.jhtml?startRow=0 & name= & tick

er=MDT> ) that federal regulation of advanced medical devices preempts

lawsuits in state courts against their manufacturers.

The case before the court Monday won't provide as broad a shield against

lawsuits as the Medtronic case, because it won't apply to all

pharmaceutical suits.

Instead, it focuses on a specific issue: whether state courts can

consider allegations that a drug company misled the Food and Drug

Administration to win approval for a drug.

In a 2001 ruling, the justices said that lawsuits alleging " fraud on the

FDA " are preempted by federal law, because they interfere with the

federal government's regulation of pharmaceuticals.

The question in this case is whether that means the exception in

Michigan's law is also preempted.

The Food and Drug Administration ordered Rezulin off the market in March

2000 after it was linked to nearly 400 deaths and hundreds of cases of

liver failure.

A group of 27 Michigan plaintiffs, including relatives of six Rezulin

patients who died from liver damage, sued Warner-Lambert after the FDA

ordered Rezulin off the market in 2000. The drug has been linked to

nearly 400 deaths.

Zieve, a lawyer for the plaintiffs, argued the Michigan law is

different than the one struck down by the court in 2001, because proving

fraud on the FDA " is just the first step to litigating " the product

liability suit. Claims of fraud against the agency aren't the focus of

the case, she said.

The court's decision could impact laws in seven other states that shield

the pharmaceutical industry from liability, but provide some exceptions

in the case of fraud.

Chief Justice has recused himself from the case. He owns

between $15,001 and $50,000 in Pfizer stock, according to his latest

financial disclosure form.

The case is Warner-Lambert v. Kent, 06-1498. A decision is expected by

July.

Copyright 2008 Associated Press. All rights reserved. This material may

not be published broadcast, rewritten, or redistributed

Kalman PhD, RD, CCRC, FACN

Miami Research Associates

Director, Nutrition & Applied Clinical Research

6141 Sunset Drive

Suite 301

Miami, FL. 33143

Ph: / 598-3125

Fax

www.miamiresearch.com <http://www.miamiresearch.com>

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...